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Abstract: Searching of new enantiomerically pure chiral derivatives of xanthones (CDXs) with
potential pharmacological properties, particularly those with anti-inflammatory activity, has remained
an area of interest of our group. Herein, we describe in silico studies and in vitro inhibitory assays of
cyclooxygenases (COX-1 and COX-2) for different enantiomeric pairs of CDXs. The evaluation of
the inhibitory activities was performed by using the COX Inhibitor Screening Assay Kit. Docking
simulations between the small molecules (CDXs; known ligands and decoys) and the enzyme targets
were undertaken with AutoDock Vina embedded in PyRx—Virtual Screening Tool software. All the
CDXs evaluated exhibited COX-1 and COX-2 inhibition potential as predicted. Considering that
the (S)-(−)-enantiomer of the nonsteroidal anti-inflammatory drug ketoprofen preferentially binds
to albumin, resulting in lower free plasma concentration than (R)-(+)-enantiomer, protein binding
affinity for CDXs was also evaluated by spectrofluorimetry as well as in in silico. For some CDXs
enantioselectivity was observed.
Keywords: chiral derivatives of xanthones; cyclooxygenase; albumin; enantioselectivity; docking
1. Introduction
A key role of chirality in drug design and development is associated with significant effects on
the behavior of this kind of compounds in vivo, with enantiomers being able to interact differently
with proteins, and other chiral biomolecules [1,2]. These events can be translated into implications
in pharmacokinetics (PK) [3], pharmacodynamics (PD) [4] as well as in toxicity [5]. Frequently only
one of the two enantiomers exerts the desired effect while the other might be inactive, less potent
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or even toxic [6,7]. Consequently, enantioselectivity can be considered an essential issue to take into
consideration when studying chiral compounds.
There are several classes of compounds illustrating the importance of chirality on both PK and
PD events such as non-steroidal anti-inflammatory drugs (NSAIDs) [8]. Considering ketoprofen, for
example, the (S)-(+)-enantiomer preferentially binds to human serum albumin (HSA), resulting in lower
free plasma concentration than (R)-(−)-enantiomer [9]. Moreover, the (S)-(+)-ketoprofen is several
times more potent than the racemate and etodolac, in which the (S)-enantiomer has cyclooxygenase
(COX) inhibitory activity whereas its antipode does not [10]. Furthermore, some NSAIDs have also
demonstrated enantioselectivity in antitumor activity, as for example (R)-enantiomer of etodolac binds
retinoid X receptor and induces tumor-selective apoptosis in malignant cells [11].
The binding of drugs to plasma proteins is an important parameter since it has implications on
drug action in vivo by affecting free concentration in serum [12,13], which has direct implications
in pharmacological effects and metabolizing processing [14]. HSA, the most abundant protein in
plasma (Mr 66 kDa, concentration 0.53 to 0.75 mM), interacts reversibly with a broad spectrum of
drugs, especially neutral and negatively charged hydrophobic compounds [15,16]. According to
current point of views in the drug discovery pipeline, the binding of new compounds with HSA at an
early stage is of crucial importance, insofar as it affects not only distribution and elimination but also
duration and intensity of the pharmacological action of drugs [12,13,17]. Moreover, enantioselectivity
for HSA binding has been reported for several drugs such as verapamil and ibuprofen [18], being also
predicted by docking studies [19,20]. One group of compounds described with antitumor [21–23],
anti-inflammatory [24–26], among others activities [27,28], concerns xanthone derivatives. Indeed, the
xanthone scaffold can be considered a privileged structure [28]. This group of oxygenated heterocyclic
compounds can be isolated from natural sources [29,30], including products from marine origin [31],
or obtained by synthesis [32,33]. Among them, synthetic chiral derivatives of xanthones (CDXs) have
also revealed interesting biological activities [34–37] and, in some cases, the activity demonstrated to
be depending on the stereochemistry of the respective molecules [36,38,39].
Search of new bioactive CDXs and investigation of enantioselectivity on their biological activity
have remained an area of interest of our group [40,41]. Recently, we described the synthesis of new
CDXs in enantiomerically pure form, and some of them exhibited growth inhibitory effects on different
tumor cell lines as well as enantioselectivity [40]. In this context, herein we described the evaluation of
COX inhibition activity and protein binding affinity for three enantiomeric pairs of CDXs (Figure 1).
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Molecular modeling studies by docking technique [42–45] were also carried out in order to
understand the interactions of the CDXs with the active site of the referred biological targets and the
structural features associated with the chiral recognition.
2. Results and Discussion
2.1. Cyclooxygenase Inhibition Studies
The effect of CDXs previously obtained in our group [40,41] as inhibitors of membrane located
enzymes that might be involved in inflammatory processes, namely COX-1 and COX-2, was evaluated.
Three enantiomeric pairs of CDXs were chosen to study the inhibitory effect of both enantiomers of
each pair face to biological targets in order to evaluate potency and enantioselectivity. The effect on
COXs activity was studied by spectrofluorimetry using a commercial kit measuring the peroxidation
activity of COXs. The kit includes isoenzyme-specific inhibitors for distinguishing COX-1 from
COX-2 activities.
The results, given as percentage (%) of inhibition and expressed as mean ± standard deviation of
two independent experiments, are summarized in Table 1. The overall results indicate that all the CDXs
evaluated exhibited COX-1 and COX-2 inhibition potential, although about 20 times less active than
indomethacin (positive control). Paired t-test was also performed to compare inhibitory effects within
each enantiomeric pair to verify the occurrence of enzyme-type and enantioselectivity. Among all the
compounds, (R)-(+)-CDX2 was the only compound presenting statistically significant enzyme-type
selectivity (p < 0.05). This enantiomer was more active at inhibiting COX-2 than COX-1. All pairs
demonstrated enantioselectivity for COX-1 and |t|calculated values were 3.613, 7.249 and 2.891 for
CDX1, CDX2 and CDX3 pairs, respectively (ttab(p = 0.05; d.f. = 10) = 2.228). (S)-(−)-CDX1, (S)-(−)-CDX2
and (S)-(+)-CDX3 were more active than their antipode.
Table 1. Inhibitory effects of CDXs on COX-1 and COX-2.
CDX COX-1 COX-2
(S)-(−)-CDX1 87.6 ± 2.1 80.1 ± 12.8
(R)-(+)-CDX1 79.6 ± 5.0 84.7 ± 5.7
(S)-(−)-CDX2 82.9 ± 5.2 85.7 ± 4.5
(R)-(+)-CDX2 66.8 ± 1.6 73.2 ± 0.4
(S)-(+)-CDX3 91.7 ± 10.7 93.4 ± 11.4
(R)-(−)-CDX3 75.2 ± 9.0 75.1 ± 7.2
Indomethacin 83.2 ± 6.4 80.7 ± 9.5
Values correspond to percentage of enzyme inhibition (mean ± standard deviation). Each compound was analyzed
in triplicate in two independent days. The concentration of CDXs was 20 µmol/L. Indomethacin 1 µmol/L was
used as positive control.
Concerning enantioselectivity for COX-2, the results obtained for the pairs of CDX2 and CDX3
should be highlighted. For instance, the % of COX-2 inhibition for (S)-(+)-CDX3 was 93.4 ± 11.4,
however the inhibitory effect of (R)-(−)-CDX3 was statistically significantly lower. |t|calculated value
was 2.891 for COX-2 (ttab(p = 0.05; d.f. = 10) = 2.228). Similarly, (S)-(−)-CDX2 was more active than
(R)-(+)-CDX2 at inhibiting COX-2 (|t|calculated = 6.777; ttab(p = 0.05; d.f. = 10) = 2.228). Accordingly, for
these two pairs, weak enantioselectivity was observed. It is important to stress that even though
enantioselectivity was observed, its extent was not as evident as that obtained for ketoprofen for
instance [10].
Molecular docking studies were also performed in order to predict the potential anti-inflammatory
activity and to postulate a hypothetical binding model of the tested compounds. The binding affinity
between the target and the small molecule was evaluated by the binding free energy approximation
(∆Gb, kcal/mol) using AutoDock Vina. The best scored conformation of each compound predicted
by AutoDock Vina was selected and further evaluated. The docking score was used to predict the
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strength of the non-covalent interactions between two molecules after they have been docked (also
referred to as binding energy). The docking score is a mathematical approximation of the binding free
energy between the ligand and its target.
Diclofenac, indomethacin, naproxen, and piroxicam [46] were used as positive controls and
showed negative binding energy values (Table 2). Ligands obtained from the database established
more stable complexes with COX-1, with an average binding free energy of −7.8 kcal/mol. Moreover,
the docking scores predicted for decoys into the COX-1 was surprisingly low (−7.3 kcal/mol). From the
tested compounds, only (S)- and (R)-CDX3 and (S)-CDX2 presented docking scores more negative than
the known COX-1 inhibitors indomethacin and piroxicam. However, as only a very small difference
was observed between known ligands and decoys scores, this model cannot be used to predict COX-1
inhibition. Hence, more detailed analysis of docking poses and binding mechanisms was performed
for the other studied COX isoform: COX-2. Diclofenac, indomethacin, celecoxib, and valdecoxib [46,47]
were used as positive controls for COX-2 inhibition. The average binding energy predicted for decoys
and known ligands into the COX-2 was−7.6 and−9.3 kcal/mol, respectively (Table 2). Both diclofenac
and indomethacin presented −7.9 kcal/mol, whereas celecoxib and valdecoxib exhibited −11.5 and
−9.5 kcal/mol, respectively. Among the tested CDXs, (R)- and (S)-CDX1 exhibited the highest binding
affinities and, therefore, lower binding free energies than negative controls.
Table 2. Docking scores of corresponding test compounds at COX-1 and COX-2 targets.
Compounds
Docking Score (kcal/mol)
COX-1 COX-2
Known ligands
Diclofenac −6.1 −7.9
Indomethacin −5.1 −7.9
Naproxen −7.8
Piroxicam −5.2
Celecoxib −11.5
Valdecoxib −9.5
Ligands from database −7.8 −9.3
Decoys from database −7.3 −7.6
(R)-(+)-CDX1 −4.2 −7.8
(S)-(−)-CDX1 −4.5 −8.0
(R)-(+)-CDX2 −3.4 −6.5
(S)-(−)-CDX2 −5.4 −7.0
(R)-(−)-CDX3 −5.3 −6.9
(S)-(+)-CDX3 −5.6 −7.5
Both positive controls and CDXs could dock into the active site of COX-2 successfully (Figure 2A).
The binding mode of celecoxib, valdecoxib, indomethacin, and diclofenac (Supplementary Data, Figure
S1) are in accordance to the previously reported binding modes. This is of particular importance
considering docking accuracy. (S)-CDX1 presented the highest binding energy (−8.0 kcal/mol) into the
COX-2 model, similar to the known ligands value. Docking energies of −7.8, −7.5, and −7.0 kcal/mol
were obtained to the (R)-CDX1, (S)-CDX3, and (S)-CDX2, respectively. CDX3 enantiomers presented
very different poses within the binding site of COX-2, whereas CDX1 enantiomers showed a minor
difference (Figure 2).
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Figure 2. (A) COX-2 ribbon representation. (B) Comparison of docking poses of CDX1 enantiomers in
COX-2 binding site. (R) and (S) enantiomers are represented in pink and yellow sticks, respectively.
(C) Comparison of docking poses of CDX3 enantiomers in COX-2 binding site. (R) and (S) enantiomers
are represented in light and dark blue sticks, respectively. Hydrogen interactions are represented as
yellow dashes and the residues evolved are represented as green lines and labeled.
CDX1 enantiomers interact through hydrogen bonds with His90, Leu352, Ser353, Tyr355, and
Ala527, also involved in the binding of kno n anti-inflammatory compounds to COX-2 [48–50]. CDX1
enantiomers bind similarly to COX-2 binding pocket, with the xanthone scaffold aligned approximately
in the same special position, with a slightly different orientation of the aromatic ring and OH group
of the chiral moiety (Figure 2B). (R)-CDX1 shows an additional hydrogen interaction between OH
and Gln-192, similarly to celecoxib and valdecoxib. On the other hand, CDX3 enantiomers bind in
very different poses in COX-2 binding pocket, almost perpendicular to each other (Figure 2C). In
fact, (S)-CDX3 (Figure 2C, dark blue sticks) binds in a pose similar to CDX1, establishing hydrogen
interactions with residues Gln192, His90, Ser353, Leu352, and Tyr355, documented as being important
for COX-2 inhibition [50–52]. Concerning (R)-CDX3, the aromatic backbone projects deep COX
active site from the hydrophobic channel, with the C3 chain establishing ydrogen interactions with
Arg513, Pro86, and Arg120, and the C6-methoxy group establishing hydrogen interactions with Tyr385
(Figure 2C, light blue sticks), which is important in the catalysis or inactivatio of the enzyme [53].
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(S)-CDX-2 establishes hydrogen interactions with Gln192, Leu352, Ser353, His90, Tyr355, and Arg513;
and (R)-CDX-2 establishes hydrogen interactions with Tyr385, Tyr355, Arg513, Pro86, and Arg-120
(not shown).
2.2. Human Serum Albumin Affinity Studies
HSA-CDX binding parameters are compiled in Table 3. The binding process has reached a
completion state as indicated by the Ymax that reached about 100%. For all the compounds, HSA
binding occurred spontaneously (∆G values < 0) in a single binding site (n = 1). All compounds
presented dissociation constants (Kd) below 100 µM, which accounts for high affinity binding to
HSA [54]. Paired t-test was performed to compare Kd obtained for (S)- and (R)-enantiomers of
each CDX pair. For all the pairs, there was a statistically significant difference between Kd values.
Hence, weak enantioselectivity concerning albumin binding was observed. Among all pairs, the
highest difference in binding affinity was observed for CDX1 (ca. 2.6 fold) as demonstrated by the
|t|calculated value which was 10.103 (ttab(p = 0.05; d.f. = 4) = 4.303). The (S)-enantiomer presented higher
binding affinity compared to the (R)-enantiomer. For CDX3 and CDX2, the difference in HSA binding
affinity obtained for (S)- and (R)-enantiomers was less pronounced compared to CDX1. For CDX2,
the (S)-enantiomer presented slightly higher affinity than the (R) one; |t|calculated value was 5.484
(ttab(p = 0.05; d.f. = 4) = 2.776). On the contrary, (R)-(−)-CDX3 has shown slightly higher affinity than
(S)-(+)-CDX3. In this case, |t|calculated value was 3.713 (ttab(p = 0.05; d.f. = 4) = 2.776).
Table 3. HSA binding parameters obtained for the CDXs and predicted docking scores between HSA
and CDXs.
Compound Kd Ymax ∆G Binding Docking Score (kcal/mol)
Known ligands
Azaprozone −5.9
Diazepam −7.1
Fusidic acid −5.8
(S)-Ibuprofen −7.3
Iophenoxid acid −4.4
Naproxen −7.9
Warfarin −8.5
(R)-(+)-CDX1 61.8 ± 6.5 109.6 ± 1.6 −2.4 ± 0.2 −7.3
(S)-(−)-CDX1 23.6 ± 0.8 105.3 ± 0.4 −1.9 ± 0.1 −7.0
(R)-(+)-CDX2 29.2 ± 0.9 108.2 ± 0.2 −2.0 ± 0.1 −7.2
(S)-(−)-CDX2 24.7 ± 1.1 107.4 ± 5.4 −1.9 ± 0.1 −7.2
(R)-(−)-CDX3 26.4 ± 1.2 113.2 ± 1.4 −1.9 ± 0.1 −7.2
(S)-(+)-CDX3 31.4 ± 2.0 116.2 ± 0.6 −2.0 ± 0.2 −7.0
Values correspond to the mean ± standard deviation of triplicate runs; Kd corresponds to the dissociation constant
of CDX-HSA in µM; Ymax corresponds to the maximum percentage of HSA fluorescence quenching; ∆G for binding
expressed in kcal/mol.
Regarding computational studies, drugs that are described as having high affinity to HSA lead
to docking scores between −4.4 kcal/mol (Iophenoxid acid) and −8.5 kcal/mol (warfarin) (Table 3).
CDXs presented scores from −7.0 to −7.3 kcal/mol, and therefore it is hypothesized that they will
have high affinity to albumin target. There is an offset between the ∆G binding and the docking scores.
This relates to the ability of the docking algorithm to predict the strength of ligand binding to the
protein target, and therefore, other scoring functions will be used in the future to increase the accuracy.
(S)-Ibuprofen binds albumin through hydrogen interactions with Arg-140, Tyr-411, and Lys-414
(Figure 3A), residues described as being involved in binding of substrates to HSA [55]. The present
study indicates that CDXs fit within the hydrophobic pocket of subdomain IIIA, presenting low
negative docking scores. This groove was selected for the docking studies as it was described
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as being the binding pocket for (S)-ibuprofen and most ligands [56]. CDXs bind in a similar
position in the binding groove, with the central xanthone ring aligned with ibuprofen ring. The
binding of CDX enantiomers in HSA subdomain IIIA present differences concerning the number of
hydrogen interactions. For example, the complex (R)-CDX1-HSA is stabilized by three hydrogen-bond
interactions with residues Leu-430, Ser-489, and Asn-391, already described as being involved in the
binding of drugs to HSA [57–59], whereas (S)-CDX1 lacks those interactions (Figure 3B). Therefore,
there is concordance between in silico and in vitro studies, as enantiosselectivity can be found on the
binding of CDX1 to HSA.
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enantiomers (B) with HSA. (R)- and (S)-enantiomers are represented in pink and yellow sticks,
respectively. Hydrogen interactions are represented as yellow dashes and the residues evolved are
represented as green lines and labeled.
3. Materials and Methods
3.1. Compounds
CDXs (Figure 1) were synthesized in enantiomerically pure form [40,41]. Briefly, a
carboxyxanthone derivative, with the structure based on some bioactive xanthones from marine
origin [31] was coupled with both enantiomers of commercially available chiral building blocks using
O-(benzotriazol-1-yl)-N-N-N’-N’-tetramethyluronium tetrafluoroborate as coupling reagent and a
catalytic amount of triethylamine in tetrahydrofuran, at room temperature. Liquid chromatography
using different types of chiral stationary phases was used to determine the enantiomeric purity of the
synthesized compounds [60,61], achieving enantiomeric excess values higher than 99%.
3.2. In vitro Cyclooxygenase Inhibition Studies
The evaluation of the inhibition of COX-1 and COX-2 by CDXs was conducted using the
commercially available COX (ovine/human) Inhibitor Screening Assay Kit (Cayman Chemical,
Michigan, MI, USA). Briefly, the assay implies an enzymatic immunoassay based on the competition
between prostaglandins (PGs) and a PG-acetylcholinesterase (AChE) conjugate (PG tracer), which
is then evaluated by the addition of Ellman’s reagent. All the solutions required for the experiment
were prepared according to the manufacturer’s instructions. Each compound was analysed in
two independent days, in triplicate. CDX working solutions were prepared in DMSO to a final
concentration of 20 µM. Indomethacin (1 µM) was used as positive control. Absorbance measurements
at 412 nm were performed in a Synergy HT microplate reader (Bio-Tek Instruments, Winooski, VT,
USA) operated with Gen5 software (Bio-Tek Instruments).
3.3. Interaction with Human Serum Albumin by Fluorescence Quenching
Evaluation of the binding of CDXs to HSA was based o the quenching of HSA intrinsic
fluorescence. Phosphate buffer consisting of 7.5 mM Na2HPO4, 1.5 mM KH2PO4 and 140 mM NaCl
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(pH 7.4) was used in the preparation of CDX solutions. Solutions of HSA fraction V (Sigma-Aldrich,
St. Louis, MO, USA) were prepared in water. Briefly, 500 µL of HSA (fixed final concentration 2 µM),
increasing volumes of drug solution (n = 13, 0–200 µM) and phosphate buffer solution (pH 7.4) were
mixed to a final volume of 1500 µL. The corresponding blank solutions were identically prepared and
analysed in the absence of the drug. Fluorescence emission spectra were recorded in the range of
300–450 nm upon excitation at 295 nm. Excitation spectra were also recorded between 220 and 310 nm
with emission set at 330 nm. For individual measurements, excitation and emission wavelength
were set at 295 nm and 330 nm, respectively. For each measurement, fluorescence emission was
automatically acquired during 180 s (5 nm bandwidth). For all compounds, UV-vis absorption spectra
(200–500 nm) were recorded. These measurements were used to correct the fluorescence intensity
values due to inner filter effects at the excitation wavelength [62]. All experiments were performed at
room temperature (25 ± 1 ◦C). Fluorescence and absorbance measurement were performed in a LS-50B
spectrometer (Perkin Elmer, Waltham, MA, USA) and a V-660 spectrophotometer (Jasco, Easton, MD,
USA) respectively.
Assessment of HSA-CDX Binding Parameters
HSA-CDX binding parameters were calculated using the Origin 8.5.1 software (8.5.1,
Northampton, MA, USA). The fitting of the experimental values was made according to the Langmuir
binding equation (Equation (1)) to calculate HSA binding parameters:
[HSA−CDX] = [HSA]
1+ Kd
[CDX]
(1)
where [HSA], [CDX] and [HSA-CDX] are given in µM and Kd corresponds to the dissociation constant
of HSA-CDX complexes.
In terms of fluorescence quenching mediated by the compound, the previous Langmuir isotherm
can be rewritten as follows (Equation (2)):
%quenching =
ymax
n
1+ Kd
[CDX]
(2)
where ymax corresponds to the highest percentage of quenching induced by a given compound and n
accounts for the number of biding sites of the enzyme to the CDX. Finally, free Gibbs energy (∆G) was
also determined for all the interactions.
3.4. Computational Studies
3.4.1. Preparation of CDXs, Controls, Decoys, and Macromolecules
The six CDXs and several known inhibitors (Tables 1 and 2) were drawn and minimized using
Universal Force Field (UFF) of Rappé and coworkers [63] which consists of a molecular mechanics
(MM) force field that includes parameterization for the entire periodic table. The calculation is
finished when the gradient between any two successive steps in the geometry search is less than
10−1 kcal/mol/Å or the maximum steps are reached, whichever comes first. The line search used is
the Broyden-Fletcher-Golfarb-Shanno search which uses an approximate Hessian matrix to guide the
search. Charges were calculated using gasteiger method [64] available in Chimera [65].
COX-1 and COX-2 decoy and ligand sets were downloaded from A Directory of Useful Decoys
(DUD) [66], a database from the University of California, San Francisco. A hundred decoys and a
hundred ligands were used for docking simulations with COX-2. Fifty decoys and the twenty three
available ligands were used for docking simulations with COX-1. These molecules were used with no
further manipulation.
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The X-ray crystal structures of COX-1 (PDB code: 3n8x) and COX-2 (PDB code: 1cx2) were
downloaded from the Protein Data Bank of Brookhaven [67]. An additional docking study was
performed using HSA as target (PDB code: 2bxg), and azaprozone, diazepam, fusidic acid, ibuprofen,
iophenoxid acid, naproxen, and warfarin as positive controls.
3.4.2. Docking
Docking simulations between the CDXs, the anti-inflammatory targets, and HSA were undertaken
in AutoDock Vina (Molecular Graphics Lab, La Jolla, CA, USA) [68]. AutoDock Vina considered
the target conformation (biomacromolecule) as a rigid unit while the ligands were allowed to be
flexible and adaptable to the target. Vina searched for the lowest binding affinity conformations and
returned nine different conformations for each CDX. The lowest binding energy docking poses of each
compound were chosen. AutoDock Vina was run using an exhaustiveness of 8 and a grid box with
the dimensions of X: 21.6, Y: 22.3, Z: 20.2 for COX-1; X: 22.9, Y: 23.7, Z: 21.7 for COX-2; and X: 18.0,
Y: 19.0, Z: 19.0 for HSA. PyMol v1.3 (Schrödinger, New York, NY, USA) [69] and Chimera (UCSF,
San Francisco, CA, USA) [65] were used for visual inspection of results and graphical representations.
4. Conclusions
All CDXs evaluated exhibited COX-1 and COX-2 inhibition in in vitro assays. Generally, the
inhibitory effects were very similar for both COXs, with exception of CDX2 enantiomeric pair. Among
all the compounds, (R)-(+)-CDX2 was more active at inhibiting COX-2 than COX-1. Interestingly, all
pairs demonstrated enantioselectivity for COX-1. Concerning COX-2, the percentage of inhibition for
(S)-(−)-CDX2 and (S)-(+)-CDX3 was higher. Accordingly, for CDX2 and CDX3 pairs enantioselectivity
for COX-2 was also observed.
Regarding in in silico studies, no significant difference was found between known ligands and
decoys docking scores on COX-1, therefore, no reliable conclusions can be taken from test ligands
binding affinity to COX-1. However, regarding docking studies with COX-2, CDX-3 enantiomers as
they presented very different poses within the binding site of the enzyme, it is reasonable to predict
enantioselectivity been in accordance to in vitro studies.
Additionally, all CDXs demonstrated to bind with high affinity to HSA in in vitro assays and weak
enantioselectivity was observed for all enantiomeric pairs. This effect was particularly evident for
CDX-1 pair. The in silico studies also confirmed that CDXs bind to HSA, as they have docking scores
similar to positive controls such as ibuprofen and diazepam; and CDX1 enantiomeric pair exhibited
enantioselectivity. Regarding HSA affinity studies, agreement between in silico and in vitro data
(activity and enantioselectivity) was achieved. Moreover, useful information about the mechanism
of molecular recognition for both COX and HSA was obtained. Even though statistical analysis
demonstrated only a trend for enantioselectivity, we envision that the introduction of molecular
modifications supported by docking studies might enhance those differences.
Taking into account the results of this study, it can be concluded that new knowledge was added
in the field of CDXs as potential anti-inflammatory agents, paving a very interesting way to understand
the enantioselectivity of this family of compounds facing to COX and HSA.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/10/2/50/s1.
Acknowledgments: This work was partially supported through national funds provided by FCT/MCTES—
Foundation for Science and Technology from the Minister of Science, Technology and Higher Education (PIDDAC)
and European Regional Development Fund (ERDF) through the COMPETE—Programa Operacional Factores
de Competitividade (POFC) programme, under the Strategic Funding UID/Multi/04423/2013, the project
PTDC/MAR-BIO/4694/2014 (reference POCI-01-0145-FEDER-016790; Project 3599—Promover a Produção
Científica e Desenvolvimento Tecnológico e a Constituição de Redes Temáticas (3599-PPCDT)) in the framework
of the programme PT2020 as well as by the project INNOVMAR - Innovation and Sustainability in the
Management and Exploitation of Marine Resources (reference NORTE-01-0145-FEDER-000035, within Research
Line NOVELMAR), supported by North Portugal Regional Operational Programme (NORTE 2020), under
the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF)
and COXANT-CESPU-2016.
Pharmaceuticals 2017, 10, 50 10 of 13
Author Contributions: Carla Fernandes contributed in writing of the manuscript and data interpretation and
analysis. Maria Elizabeth Tiritan participated in discussion of the results. Carlos Carneiro performed docking
studies with COXs. Andreia Palmeira performed docking studies with HSA, contributed in the data analysis
carried out in both in silico studies, and contributed in writing of the manuscript. Honorina Cidade participated
in vitro COXs inhibition experiments. Inês I. Ramos performed both in vitro experiments and contributed in
writing of the manuscript. Paula C.A.G. Pinto contributed in the data analysis carried out in vitro COXs inhibition
studies. M. Lúcia M.F.S. Saraiva and Carlos Afonso gave scientific advice for the development of in vitro HSA
affinity studies. Salette Reis coordinated and supervised the in vitro experiments and reviewed the data generated.
Corresponding author Madalena M.M. Pinto conceived and designed the experiments, supervised the project,
discussed results, and led the preparation of the manuscript.
Conflicts of Interest: The authors declare no conflict of interest
References
1. Tiritan, M.E.; Ribeiro, A.R.; Fernandes, C.; Pinto, M. Chiral pharmaceuticals. In Kirk-Othmer Encyclopedia of
Chemical Technology; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2016; pp. 1–28.
2. Blaser, H.U. Chirality and its implications for the pharmaceutical industry. Rend. Lincei 2013, 24, 213–216.
[CrossRef]
3. Brocks, D.R. Drug disposition in three dimensions: An update on stereoselectivity in pharmacokinetics.
Biopharm. Drug Dispos. 2006, 27, 387–406. [CrossRef] [PubMed]
4. Mannschreck, A.; Kiesswetter, R.; von Angerer, E. Unequal activities of enantiomers via biological receptors:
Examples of chiral drug, pesticide, and fragrance molecules. J. Chem. Educ. 2007, 84, 2012–2017. [CrossRef]
5. Smith, S.W. Chiral toxicology: It's the same thing only different. Toxicol. Sci. 2009, 110, 4–30. [CrossRef]
[PubMed]
6. Sekhon, B.S. Exploiting the power of stereochemistry in drugs: An overview of racemic and enantiopure
drugs. J. Mod. Med. Chem. 2013, 1, 10–36. [CrossRef]
7. Triggle, D.J. Stereoselectivity of drug action. Drug Discov. Today 1997, 2, 138–147. [CrossRef]
8. Kasprzyk-Hordern, B. Pharmacologically active compounds in the environment and their chirality.
Chem. Soc. Rev. 2010, 39, 4466–4503. [CrossRef] [PubMed]
9. Moreno, J.J.; Calvo, L.; Fernandez, F.; Carganico, G.; Bastida, E.; Bujons, J.; Messeguer, A. Biological activity
of ketoprofen and its optical isomers. Eur. J. Pharmacol. 1990, 183, 2263–2264. [CrossRef]
10. Sánchez, T.; Moreno, J.J. ketoprofen S(+)-enantiomer inhibits prostaglandin production and cell growth in
3T6 fibroblast cultures. Eur. J. Pharmacol. 1999, 370, 63–67. [CrossRef]
11. Kolluri, S.K.; Corr, M.; James, S.Y.; Bernasconi, M.; Lu, D.; Liu, W.; Cottam, H.B.; Leoni, L.M.; Carson, D.A.;
Zhang, X.K. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid x receptor
and induces tumor-selective apoptosis. Proc. Natl. Acad. Sci. USA 2005, 102, 2525–2530. [CrossRef] [PubMed]
12. Trainor, G.L. The importance of plasma protein binding in drug discovery. Expert Opin. Drug Discov. 2007, 2,
51–64. [CrossRef] [PubMed]
13. Kerns, E.H.; Di, L. Drug-Like Properties: Concepts, Structure Design and Methods; Elsevier Inc.: Burlington, MA,
USA, 2008.
14. Fasano, M.; Curry, S.; Terreno, E.; Galliano, M.; Fanali, G.; Narciso, P.; Notari, S.; Ascenzi, P. The extraordinary
ligand binding properties of human serum albumin. IUBMB Life 2005, 57, 787–796. [CrossRef] [PubMed]
15. Shen, Q.; Wang, L.; Zhou, H.; Jiang, H.D.; Yu, L.S.; Zeng, S. Stereoselective binding of chiral drugs to plasma
proteins. Acta Pharmacol. Sin. 2013, 34, 998–1006. [CrossRef] [PubMed]
16. Goodman, G.; Gilman. The Pharmacological Basis of Therapeutics, 9th ed.; McGraw-Hill: New York, NY,
USA, 1996.
17. Kratochwil, N.A.; Huber, W.; Müller, F.; Kansy, M.; Gerber, P.R. Predicting plasma protein binding of drugs:
A new approach. Biochem. Pharmacol. 2002, 64, 1355–1374. [CrossRef]
18. Oravcova, J.; Bohs, B.; Lindner, W. Drug-protein binding studies—new trends in analytical and experimental
methodology. J. Chromatogr. B Biomed. Appl. 1996, 677, 1–28. [CrossRef]
19. Paal, K.; Shkarupin, A. Paclitaxel binding to the fatty acid-induced conformation of human serum
albumin—automated docking studies. Bioorg. Med. Chem. 2007, 15, 7568–7575. [CrossRef] [PubMed]
20. Tang, B.; Huang, Y.M.; Ma, X.L.; Liao, X.X.; Wang, Q.; Xiong, X.N.; Li, H. Multispectroscopic and docking
studies on the binding of chlorogenic acid isomers to human serum albumin: Effects of esteryl position on
affinity. Food Chem. 2016, 212, 434–442. [CrossRef] [PubMed]
Pharmaceuticals 2017, 10, 50 11 of 13
21. Pouli, N.; Marakos, P. Fused xanthone derivatives as antiproliferative agents. Anticancer Agents Med. Chem.
2009, 9, 77–98. [CrossRef] [PubMed]
22. Palmeira, A.; Paiva, A.; Sousa, E.; Seca, H.; Almeida, G.M.; Lima, R.T.; Fernandes, M.X.; Pinto, M.;
Vasconcelos, M.H. Insights into the in vitro antitumor mechanism of action of a new pyranoxanthone.
Chem. Biol. Drug Des. 2010, 76, 43–58. [CrossRef] [PubMed]
23. Sousa, E.; Paiva, A.; Nazareth, N.; Gales, L.; Damas, A.M.; Nascimento, M.S.J.; Pinto, M.
Bromoalkoxyxanthones as promising antitumor agents: Synthesis, crystal structure and effect on human
tumor cell lines. Eur. J. Med. Chem. 2009, 44, 3830–3835. [CrossRef] [PubMed]
24. Panthong, K.; Hutadilok-Towatana, N.; Panthong, A. Cowaxanthone f, a new tetraoxygenated xanthone, and
other anti-inflammatory and antioxidant compounds from garcinia cowa. Can. J. Chem. 2009, 87, 1636–1640.
[CrossRef]
25. Nakatani, K.; Nakahata, N.; Arakawa, T.; Yasuda, H.; Ohizumi, Y. Inhibition of cyclooxygenase and
prostaglandin E2 synthesis by γ-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells.
Biochem. Pharmacol. 2002, 63, 73–79. [CrossRef]
26. Nakatani, K.; Yamakuni, T.; Kondo, N.; Arakawa, T.; Oosawa, K.; Shimura, S.; Inoue, H.;
Ohizumi, Y. Γ-mangostin inhibits inhibitor-κB kinase activity and decreases lipopolysaccharide-lnduced
cyclooxygenase-2 gene expression in C6 rat glioma cells. Mol. Pharmacol. 2004, 66, 667–674. [CrossRef]
[PubMed]
27. Shagufta; Ahmad, I. Recent insight into the biological activities of synthetic xanthone derivatives. Eur. J.
Med. Chem. 2016, 116, 267–280.
28. Pinto, M.M.M.; Sousa, M.E.; Nascimento, M.S.J. Xanthone derivatives: New insights in biological activities.
Curr. Med. Chem. 2005, 12, 2517–2538. [CrossRef] [PubMed]
29. Vieira, L.M.M.; Kijjoa, A. Naturally-occurring xanthones: Recent developments. Curr. Med. Chem. 2005, 12,
2413–2446. [CrossRef] [PubMed]
30. Masters, K.S.; Bräse, S. Xanthones from fungi, lichens, and bacteria: The natural products and their synthesis.
Chem. Rev. 2012, 112, 3717–3776. [CrossRef] [PubMed]
31. Pinto, M.M.M.; Castanheiro, R.A.P.; Kijjoa, A. Xanthones from marine-derived microorganisms: Isolation,
structure elucidation, and biological activities. In Encyclopedia of Analytical Chemistry; John Wiley & Sons,
Ltd.: Hoboken, NJ, USA, 2014; Vol. 27, pp. 1–21.
32. Azevedo, C.M.G.; Afonso, C.M.M.; Sousa, D.; Lima, R.T.; Helena Vasconcelos, M.; Pedro, M.; Barbosa, J.;
Corrêa, A.G.; Reis, S.; Pinto, M.M.M. Multidimensional optimization of promising antitumor xanthone
derivatives. Bioorg. Med. Chem. 2013, 21, 2941–2959. [CrossRef] [PubMed]
33. Sousa, M.E.; Pinto, M.M.M. Synthesis of xanthones: An overview. Curr. Med. Chem. 2005, 12, 2447–2479.
[CrossRef] [PubMed]
34. Waszkielewicz, A.M.; Słoczyn´ska, K.; Pe˛kala, E.; Z˙mudzki, P.; Siwek, A.; Grybos´, A.; Marona, H. Design,
synthesis, and anticonvulsant activity of some derivatives of xanthone with aminoalkanol moieties.
Chem. Biol. Drug Des. 2017, 89, 339–352. [CrossRef] [PubMed]
35. Szkaradek, N.; Rapacz, A.; Pytka, K.; Filipek, B.; Siwek, A.; Cegła, M.; Marona, H. Synthesis and preliminary
evaluation of pharmacological properties of some piperazine derivatives of xanthone. Bioorg. Med. Chem.
2013, 21, 514–522. [CrossRef] [PubMed]
36. Marona, H.; Pekala, E.; Antkiewicz-Michaluk, L.; Walczak, M.; Szneler, E. Anticonvulsant activity of some
xanthone derivatives. Bioorg. Med. Chem. 2008, 16, 7234–7244. [CrossRef] [PubMed]
37. Sousa, E.P.; Silva, A.M.S.; Pinto, M.M.M.; Pedro, M.M.; Cerqueira, F.A.M.; Nascimento, M.S.J. Isomeric
kielcorins and dihydroxyxanthones: Synthesis, structure elucidation, and inhibitory activities of growth of
human cancer cell lines and on the proliferation of human lymphocytes in vitro. Hel. Chim. Acta 2002, 85,
2862–2876. [CrossRef]
38. Rewcastle, G.W.; Atwell, G.J.; Baguley, B.C.; Boyd, M.; Thomsen, L.L.; Zhuang, L.; Denny, W.A. Potential
antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent
9-oxo-9h-xanthene-4-acetic acid. J. Med. Chem. 1991, 34, 2864–2870. [CrossRef] [PubMed]
39. Sousa, M.E.; Tiritan, M.E.; Belaz, K.R.A.; Pedro, M.; Nascimento, M.S.J.; Cass, Q.B.; Pinto, M.M.M.
Multimilligram enantioresolution of low-solubility xanthonolignoids on polysaccharide chiral stationary
phases using a solid-phase injection system. J. Chromatogr. A 2006, 1120, 75–81. [CrossRef] [PubMed]
Pharmaceuticals 2017, 10, 50 12 of 13
40. Fernandes, C.; Masawang, K.; Tiritan, M.E.; Sousa, E.; De Lima, V.; Afonso, C.; Bousbaa, H.; Sudprasert, W.;
Pedro, M.; Pinto, M.M. New chiral derivatives of xanthones: Synthesis and investigation of enantioselectivity
as inhibitors of growth of human tumor cell lines. Bioorg. Med. Chem. 2014, 22, 1049–1062. [CrossRef]
[PubMed]
41. Fernandes, C.; Oliveira, L.; Tiritan, M.E.; Leitao, L.; Pozzi, A.; Noronha-Matos, J.B.; Correia-De-Sá, P.;
Pinto, M.M. Synthesis of new chiral xanthone derivatives acting as nerve conduction blockers in the rat
sciatic nerve. Eur. J. Med. Chem. 2012, 55, 1–11. [CrossRef] [PubMed]
42. Cidade, H.; Rocha, V.; Palmeira, A.; Marques, C.; Tiritan, M.E.; Ferreira, H.; Lobo, J.S.; Almeida, I.F.;
Sousa, M.E.; Pinto, M. In silico and in vitro antioxidant and cytotoxicity evaluation of oxygenated xanthone
derivatives. Arab. J. Chem. 2017, in press. [CrossRef]
43. Pereira, D.; Lima, R.T.; Palmeira, A.; Seca, H.; Soares, J.; Gomes, S.; Raimundo, L.; Maciel, C.; Pinto, M.;
Sousa, E.; et al. Design and synthesis of new inhibitors of p53-MDM2 interaction with a chalcone scaffold.
Arab. J. Chem. 2016, in press. [CrossRef]
44. Palmeira, A.; Rodrigues, F.; Sousa, E.; Pinto, M.; Vasconcelos, M.H.; Fernandes, M.X. New uses for old drugs:
Pharmacophore-based screening for the discovery of p-glycoprotein inhibitors. Chem. Biol. Drug Des. 2011,
78, 57–72. [CrossRef] [PubMed]
45. Lima, R.T.; Seca, H.; Palmeira, A.; Fernandes, M.X.; Castro, F.; Correia-da-Silva, M.; Nascimento, M.S.J.;
Sousa, E.; Pinto, M.; Vasconcelos, M.H. Sulfated small molecules targeting EBV in Burkitt lymphoma: From
in silico screening to the evidence of in vitro effect on viral episomal DNA. Chem. Biol. Drug Des. 2013, 81,
631–644. [CrossRef] [PubMed]
46. Hawkey, C.J. Cox-1 and cox-2 inhibitors. Best Pract. Res. Clin. Gastroenterol. 2001, 15, 801–820. [CrossRef]
[PubMed]
47. Atukorala, I.; Hunter, D.J. Valdecoxib: The rise and fall of a cox-2 inhibitor. Expert Opin. Pharmacother. 2013,
14, 1077–1086. [CrossRef] [PubMed]
48. Bali, A.; Ohri, R.; Deb, P.K. Synthesis, evaluation and docking studies on 3-alkoxy-4-methanesulfonamido
acetophenone derivatives as non-ulcerogenic anti-inflammatory agents. Eur. J. Med. Chem. 2012, 49, 397–405.
[CrossRef] [PubMed]
49. Hegazy, G.H.; Ali, H.I. Design, synthesis, biological evaluation, and comparative cox1 and cox2 docking of
p-substituted benzylidenamino phenyl esters of ibuprofenic and mefenamic acids. Bioorg. Med. Chem. 2012,
20, 1259–1270. [CrossRef] [PubMed]
50. El-Sayed, M.A.; Abdel-Aziz, N.I.; Abdel-Aziz, A.A.; El-Azab, A.S.; ElTahir, K.E. Synthesis, biological
evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective cox-2 inhibitors
and anti-inflammatory agents. Part 2. Bioorg. Med. Chem. 2012, 20, 3306–3316. [CrossRef] [PubMed]
51. Ryn, J.; Trummlitz, G.; Pairet, M. Cox-2 selectivity and inflammatory processes. Curr. Med. Chem. 2000, 7,
1145–1161. [CrossRef] [PubMed]
52. Abdel-Aziz, A.A.; ElTahir, K.E.; Asiri, Y.A. Synthesis, anti-inflammatory activity and cox-1/cox-2 inhibition
of novel substituted cyclic imides. Part 1: Molecular docking study. Eur. J. Med. Chem. 2011, 46, 1648–1655.
[CrossRef] [PubMed]
53. Rowlinson, S.W.; Kiefer, J.R.; Prusakiewicz, J.J.; Pawlitz, J.L.; Kozak, K.R.; Kalgutkar, A.S.; Stallings, W.C.;
Kurumbail, R.G.; Marnett, L.J. A novel mechanism of cyclooxygenase-2 inhibition involving interactions
with ser-530 and tyr-385. J. Biol. Chem. 2003, 278, 45763–45769. [CrossRef] [PubMed]
54. Parikh, H.H.; McElwain, K.; Balasubramanian, V.; Leung, W.; Wong, D.; Morris, M.E.; Ramanathan, M.
A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for
high-throughput screening. Pharm. Res. 2000, 17, 632–637. [CrossRef] [PubMed]
55. Watanabe, H.; Tanase, S.; Nakajou, K.; Maruyama, T.; Kragh-Hansen, U.; Otagiri, M. Role of arg-410 and
tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem. J. 2000, 349 Pt 3,
813–819. [CrossRef] [PubMed]
56. Ghuman, J.; Zunszain, P.A.; Petitpas, I.; Bhattacharya, A.A.; Otagiri, M.; Curry, S. Structural basis of the
drug-binding specificity of human serum albumin. J. Mol. Biol. 2005, 353, 38–52. [CrossRef] [PubMed]
57. Zaidi, N.; Ahmad, E.; Rehan, M.; Rabbani, G.; Ajmal, M.R.; Zaidi, Y.; Subbarao, N.; Khan, R.H. Biophysical
insight into furosemide binding to human serum albumin: A study to unveil its impaired albumin binding
in uremia. J. Phys. Chem. B 2013, 117, 2595–2604. [CrossRef] [PubMed]
Pharmaceuticals 2017, 10, 50 13 of 13
58. Karthikeyan, S.; Bharanidharan, G.; Mani, K.A.; Srinivasan, N.; Kesherwani, M.; Velmurugan, D.; Aruna, P.;
Ganesan, S. Determination on the binding of thiadiazole derivative to human serum albumin: A spectroscopy
and computational approach. J. Biomol. Struct. Dyn. 2016, 1–12. [CrossRef] [PubMed]
59. Singh, D.V.; Bharti, S.K.; Agarwal, S.; Roy, R.; Misra, K. Study of interaction of human serum albumin with
curcumin by nmr and docking. J. Mol. Model. 2014, 20, 2365. [CrossRef] [PubMed]
60. Fernandes, C.; Brandão, P.; Santos, A.; Tiritan, M.E.; Afonso, C.; Cass, Q.B.; Pinto, M.M. Resolution and
determination of enantiomeric purity of new chiral derivatives of xanthones using polysaccharide-based
stationary phases. J. Chromatogr. A 2012, 1269, 143–153. [CrossRef] [PubMed]
61. Fernandes, C.; Tiritan, M.E.; Cass, Q.; Kairys, V.; Fernandes, M.X.; Pinto, M. Enantioseparation and chiral
recognition mechanism of new chiral derivatives of xanthones on macrocyclic antibiotic stationary phases.
J. Chromatogr. A 2012, 1241, 60–68. [CrossRef] [PubMed]
62. Coutinho, A.; Prieto, M. Ribonuclease t1 and alcohol dehydrogenase fluorescence quenching by
acrylamide—A laboratory experiment for undergraduate students. J. Chem. Edu. 1993, 70, 425–428.
[CrossRef]
63. Casewit, C.J.; Colwell, K.S.; Rappe, A.K. Application of a universal force field to main group compounds.
J. Am. Chem. Soc. 1992, 114, 10046–10053. [CrossRef]
64. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity—A rapid access to atomic
charges. Tetrahedron 1980, 36, 3219–3228. [CrossRef]
65. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF
chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612.
[CrossRef] [PubMed]
66. Mysinger, M.M.; Carchia, M.; Irwin, J.J.; Shoichet, B.K. Directory of useful decoys, enhanced (DUD-E): Better
ligands and decoys for better benchmarking. J. Med. Chem. 2012, 55, 6582–6594. [CrossRef] [PubMed]
67. Rose, P.W.; Prlic, A.; Bi, C.; Bluhm, W.F.; Christie, C.H.; Dutta, S.; Green, R.K.; Goodsell, D.S.; Westbrook, J.D.;
Woo, J.; et al. The RCSB protein data bank: Views of structural biology for basic and applied research and
education. Nucleic Acids Res. 2015, 43, D345–D356. [CrossRef] [PubMed]
68. Trott, O.; Olson, A.J. Autodock vina: Improving the speed and accuracy of docking with a new scoring
function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455–461. [CrossRef]
[PubMed]
69. Seeliger, D.; de Groot, B.L. Ligand docking and binding site analysis with pymol and autodock/vina.
J. Comput. Aided Mol. Des. 2010, 24, 417–422. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
